Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

Core Viewpoint - Molecular Partners AG is advancing its clinical-stage development of MP0533, a novel tetra-specific T cell engager for treating acute myeloid leukemia (AML), with updated data to be presented at the upcoming ASH Annual Meeting [1][2]. Group 1: Clinical Trial Details - The Phase 1/2a trial of MP0533 is a first-in-human, multicenter, open-label study focusing on relapsed/refractory AML and myelodysplastic syndrome (MDS)/AML patients [2]. - Initial results indicate that MP0533 has an acceptable safety profile across dosing regimens DR 1–9, with encouraging preliminary signs of antitumor activity [2]. - The study is currently in the dosing phase for patients in DR 10 [2]. Group 2: Mechanism of Action - MP0533 is designed to engage T cells by targeting three tumor-associated antigens (CD33, CD123, and CD70) on AML cells, as well as the immune activator CD3 on T cells [3]. - This tetra-specific approach allows MP0533 to preferentially bind to AML cells, which commonly express multiple target antigens, while minimizing binding to healthy cells [3]. Group 3: Presentation Details - The presentation at the ASH Annual Meeting will include initial results from the optimized treatment regimen of MP0533, including densified dosing and adapted premedication [4]. - The session is scheduled for December 7, 2025, from 6:00–8:00 PM ET, with the full abstracts available on the ASH website [4]. Group 4: About DARPin Therapeutics - DARPin therapeutics represent a new class of custom-built protein drugs that offer multi-target specificity and high stability, providing advantages over traditional protein-based therapeutics [5]. - The DARPin platform is designed for rapid and cost-effective drug discovery, producing candidates with optimized properties and high production yields [5]. Group 5: Company Overview - Molecular Partners AG focuses on developing DARPin therapeutics to address medical challenges that other drug modalities cannot effectively target, with oncology as its primary area of focus [6]. - The company has been operational since 2004 and maintains offices in Zurich, Switzerland, and Concord, Massachusetts, USA [6].